Rainbow Seed Fund News

— Early-stage venture fund key in bridging gap between UK research and commercialisation — Fund aims to turn UK scientific ‘world’s first’ ambitions into market-leading companies Rainbow Seed Fund, an early-stage venture capital fund focused on promising technologies developed at the UK’s largest publicly-funded research facilities and campuses, today announces that the fund have now […]

read more

CellCentric is developing first in class drug compounds against a key regulator of cancer. P300/CBP are twin (paralogue) histone acetyltransferase proteins, that act as transcriptional co-factors. When inhibited they cause the down regulation of the androgen receptor (AR) and its variants. It also decreases c-Myc, another key cancer driver. CellCentric has been focusing the use […]

read more

Collaboration to generate tumor targeting drug conjugates and immuno-oncology therapeutics Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody®-based therapeutics, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced a global, strategic, multi-target collaboration and license agreement for the discovery, development and commercialization of Humabody® -based therapeutics for cancer indications with a high unmet medical […]

read more

1 2 3 4 5 19